Evidence map›Paper›PMID 40938575›Full record

ArticleInternational journal of hematology2025

Genetic prognostic markers in LymphGen-unclassifiable diffuse large B cell lymphoma.

Yusuke Kanemasa, Daichi Sadato, Maya Isogai, Mina Ogawa, Chizuko Hirama, Hideya Kawaji, Tatsuro Yamaguchi, Yuka Harada, Tsunekazu Hishima, Keisuke Oboki and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yusuke Kanemasa *Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. yuusuke_kanemasa@tmhp.jp.ORCID http://orcid.org/0000-0002-9809-2008
Daichi Sadato *Research Center for Genome and Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Maya IsogaiResearch Center for Genome and Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Mina OgawaResearch Center for Genome and Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Chizuko HiramaResearch Center for Genome and Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Hideya KawajiResearch Center for Genome and Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Tatsuro YamaguchiDepartment of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Yuka HaradaClinical Research Support Center, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Tsunekazu HishimaDepartment of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Keisuke ObokiResearch Center for Genome and Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. ooboki-ks@igakuken.or.jp.
Tatsu ShimoyamaDepartment of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.

Funding

the Japan Society for the Promotion of Science (JSPS) KAKENHI 20K07818the Japan Society for the Promotion of Science (JSPS) KAKENHI 21K07231the Japan Society for the Promotion of Science (JSPS) KAKENHI 21K07407
6 · The paper itself

Abstract

Diffuse large B cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, has variable treatment responses and distinct molecular subtypes. Despite therapeutic advances, a significant number of patients experience treatment failure or relapse. Recent genetic subtyping methods, such as the LymphGen algorithm, classify DLBCL into molecular subtypes. However, a subset of cases remains categorized as "LymphGen-unclassifiable" ("Other" group in the LymphGen classification). These cases lack distinctive genetic features and present challenges for risk assessment. In this study, we aimed to identify prognostic genetic markers specific to LymphGen-unclassifiable DLBCL. Using a discovery cohort from the National Cancer Institute, we identified genetic alterations in CDKN2A and PIM1 that were significantly associated with overall survival in this patient group. We then validated the model in a separate cohort from Komagome Hospital in Tokyo. Our model, combined with the International Prognostic Index (IPI), identified high-risk LymphGen-unclassifiable DLBCL patients within the high-risk IPI group, showing a 2-year overall survival rate of 38% versus 72%. This approach could support the development of more targeted therapies by improving prognostic accuracy and advancing understanding of LymphGen-unclassifiable DLBCL.

Indexed as

Biomarkers, TumorLymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overCyclin-Dependent Kinase Inhibitor p16FemaleGenetic MarkersHumansMaleMiddle AgedPrognosisProto-Oncogene Proteins c-pim-1Survival RateBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Genetic MarkersProto-Oncogene Proteins c-pim-1Diffuse large B cell lymphomaGenetic subtypeGenomic alterationsMolecular classificationPrognostic scoring model

Identifiers

PMID40938575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.